Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. JCO Dec 1, 2009:5794-5799; published online on October 13, 2009.

Yip S, Wells C, Moreira RB, et al. Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC. JCO (Abstract).

Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus SUNItinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591-597.

Wells JC, Stukalin I, Norton C, et al. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2017;71(2):204-209.

Motzer RJ, Tannir NM, Mcdermott DF, et al. Nivolumab plus Ipilimumab versus SUNItinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290.

Heng DY, Xie W, Regan MM et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2),141-148.

Kroeger N, Xie W, Lee JL, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013;119(16):2999-3006.

Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16(3):293-300.

Dr. Daniel Heng

Dr. Toni Choueiri

Dr. Wanling Xie

IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma

perf

neut

Predicts survival in patients with metastatic renal cell carcinoma treated with systemic therapy (also known as Heng criteria).

IMDC Model for mRCC

Ziad Bakouny, MD, MSc, is a postdoctoral genitourinary oncology research fellow at the Dana-Farber Cancer Institute/Harvard Cancer Center. Dr. Bakouny received his medical degree from the University of Saint Joseph in Beirut, Lebanon, during which time he concurrently obtained a master’s in biomechanics and medical imaging. He has published more than 30 peer-reviewed papers, presented 70 abstracts at international scientific conferences, and received various awards for his research, including a Conquer Cancer Foundation merit award at the American Society of Clinical Oncology and Society for Immunotherapy of Cancer’s clinical immuno-oncology symposium. His areas of interest include genitourinary oncology, biomarker research, and bioinformatics.

Ziad Bakouny, MD, MSc

The IMDC (International Metastatic RCC Database Consortium) Risk Score for RCC predicts survival patients in metastatic renal cell carcinoma treated with systemic therapy.

UISS for RCC

MSKCC/Motzer Criteria for RCC

RENAL Nephrometry Score

EB Medicine is the premier provider of evidence-based clinical content and CME resources for emergency medicine practitioners.

Listen to the VACO co-creators break down how to use VACO\, what it does\, and what it doesn’t.

Calc Function